A low-cost, lightweight, and fully compostable biocomposite made from amylopectin and cellulose fibers designed to replace polystyrene foam packaging. Offers high stiffness (~2 GPa) and strength (~32 MPa) at densities below 1 g/cm³, with strong water resistance and natural sourcing from food and plant resources.
This solution is a compostable biocomposite engineered from amylopectin and cellulose fibers to serve as a sustainable alternative to polystyrene (PS) foam. By leveraging the highly branched molecular structure of amylopectin, the material forms a gel-like network that bonds strongly with cellulose fibers under controlled thermal treatment and recrystallization. The result is a strong, lightweight, low-cost material derived entirely from abundant natural sources such as starch, sticky rice, and plant fibers. It is intended for packaging and other foam-replacement applications where compostability, mechanical performance, and cost are critical decision factors.
Key features and performance:
Development roadmap:
The biocomposite concept has been validated through prior published research demonstrating its mechanical performance, microstructural integrity, and improved water resistance compared with other natural materials. The current proposal advances the technology through three specific aims focused on optimizing the composite recipe, scaling manufacturing processes, and completing standardized compostability and durability testing. The technology is at an early-to-mid stage of development, transitioning from laboratory validation toward process optimization and standard characterization required for commercial packaging applications.
The University of Oklahoma is a flagship public research university spanning Norman, Oklahoma City, and Tulsa, combining comprehensive academics with a major health sciences center. Industry collaborates through a research and technology campus in Norman that co‑locates university facilities with federal partners, and through the OU Health Sciences Center, which connects clinicians, core labs, and clinical trials within the OU Health system. Dedicated corporate engagement and contracting teams streamline sponsored research, while a centralized technology commercialization office supports IP, licensing, and startup formation. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD.